Weekly Chemotherapy with Cisplatin and Paclitaxel and Concurrent Radiation Therapy as Preoperative Treatment in Locally Advanced Esophageal Cancer: A Phase II Study

Michele OrdituraDivision of Medical Oncology, Division of Surgical Oncology, Department of Clinical and Experimental Medicine and Surgery “F. Magrassi e A. Lanzara”, Second University of Naples, School of Medicine, Naples, Italy, Division of Radiotherapy, Federico II University of Naples, School of Medicine, Naples, Italy

Gennaro GaliziaDivision of Medical Oncology, Division of Surgical Oncology, Department of Clinical and Experimental Medicine and Surgery “F. Magrassi e A. Lanzara”, Second University of Naples, School of Medicine, Naples, Italy, Division of Radiotherapy, Federico II University of Naples, School of Medicine, Naples, Italy

Vincenzo NapolitanoDivision of Medical Oncology, Division of Surgical Oncology, Department of Clinical and Experimental Medicine and Surgery “F. Magrassi e A. Lanzara”, Second University of Naples, School of Medicine, Naples, Italy, Division of Radiotherapy, Federico II University of Naples, School of Medicine, Naples, Italy

Erika MartinelliDivision of Medical Oncology, Division of Surgical Oncology, Department of Clinical and Experimental Medicine and Surgery “F. Magrassi e A. Lanzara”, Second University of Naples, School of Medicine, Naples, Italy, Division of Radiotherapy, Federico II University of Naples, School of Medicine, Naples, Italy

Roberto PacelliDivision of Medical Oncology, Division of Surgical Oncology, Department of Clinical and Experimental Medicine and Surgery “F. Magrassi e A. Lanzara”, Second University of Naples, School of Medicine, Naples, Italy, Division of Radiotherapy, Federico II University of Naples, School of Medicine, Naples, Italy

Eva LietoDivision of Medical Oncology, Division of Surgical Oncology, Department of Clinical and Experimental Medicine and Surgery “F. Magrassi e A. Lanzara”, Second University of Naples, School of Medicine, Naples, Italy, Division of Radiotherapy, Federico II University of Naples, School of Medicine, Naples, Italy

Gaetano AurilioDivision of Medical Oncology, Division of Surgical Oncology, Department of Clinical and Experimental Medicine and Surgery “F. Magrassi e A. Lanzara”, Second University of Naples, School of Medicine, Naples, Italy, Division of Radiotherapy, Federico II University of Naples, School of Medicine, Naples, Italy

Loredana VecchioneDivision of Medical Oncology, Division of Surgical Oncology, Department of Clinical and Experimental Medicine and Surgery “F. Magrassi e A. Lanzara”, Second University of Naples, School of Medicine, Naples, Italy, Division of Radiotherapy, Federico II University of Naples, School of Medicine, Naples, Italy

Floriana MorgilloDivision of Medical Oncology, Division of Surgical Oncology, Department of Clinical and Experimental Medicine and Surgery “F. Magrassi e A. Lanzara”, Second University of Naples, School of Medicine, Naples, Italy, Division of Radiotherapy, Federico II University of Naples, School of Medicine, Naples, Italy

Giuseppe CatalanoDivision of Medical Oncology, Division of Surgical Oncology, Department of Clinical and Experimental Medicine and Surgery “F. Magrassi e A. Lanzara”, Second University of Naples, School of Medicine, Naples, Italy, Division of Radiotherapy, Federico II University of Naples, School of Medicine, Naples, Italy

Fortunato CiardielloDivision of Medical Oncology, Division of Surgical Oncology, Department of Clinical and Experimental Medicine and Surgery “F. Magrassi e A. Lanzara”, Second University of Naples, School of Medicine, Naples, Italy, Division of Radiotherapy, Federico II University of Naples, School of Medicine, Naples, Italy

Alberto Del GenioDivision of Medical Oncology, Division of Surgical Oncology, Department of Clinical and Experimental Medicine and Surgery “F. Magrassi e A. Lanzara”, Second University of Naples, School of Medicine, Naples, Italy, Division of Radiotherapy, Federico II University of Naples, School of Medicine, Naples, Italy

Natale Di MartinoDivision of Medical Oncology, Division of Surgical Oncology, Department of Clinical and Experimental Medicine and Surgery “F. Magrassi e A. Lanzara”, Second University of Naples, School of Medicine, Naples, Italy, Division of Radiotherapy, Federico II University of Naples, School of Medicine, Naples, Italy

Ferdinando De VitaDivision of Medical Oncology, Division of Surgical Oncology, Department of Clinical and Experimental Medicine and Surgery “F. Magrassi e A. Lanzara”, Second University of Naples, School of Medicine, Naples, Italy, Division of Radiotherapy, Federico II University of Naples, School of Medicine, Naples, Italy

show all

ABSTRACT

We evaluated the association of a weekly cisplatin (35 mg/mq) and paclitaxel (45 mg/mq) regimen with radiotherapy (46 Gy) as primary treatment in locally advanced esophageal cancer (LAEC). The main end point was the activity in terms of pathologic complete response (pathCR) rate. Thirty-three LAEC patients received chemoradiation therapy during weeks 1–6 followed by esophagectomy. A pathCR was observed in 10/33 patients; 20/33 and 3/33 patients showed PR and SD, respectively. The EUS maximal transverse cross sectional area reduction >50% significantly correlated with pathCR. Three-year survival rate was 35%. These results support the activity and mild toxicity of this regimen.

Keywords: :

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Weekly Chemotherapy with Cisplatin and Paclitaxel and Concurrent Radiation Therapy as Preoperative Treatment in Locally Advanced Esophageal Cancer: A Phase II Study

Information for

Open access

Opportunities

Help and information

Weekly Chemotherapy with Cisplatin and Paclitaxel and Concurrent Radiation Therapy as Preoperative Treatment in Locally Advanced Esophageal Cancer: A Phase II Study

ABSTRACT

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature